You can buy or sell MyoKardia and other stocks, options, ETFs, and crypto commission-free!
MyoKardia, Inc. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases. Read More The firm focuses on the treatment of heritable cardiomyopathies, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It offers MYK-46, an orally-administered small molecule designed to reduce excessive cardiac muscle contractility to hypertrophic cardiomyopathy. The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in San Francisco, CA.
San Francisco, California
52 Week High
52 Week Low
Seeking AlphaMar 11
MyoKardia: Addressing An Unmet Need In Hypertrophic Cardiomyopathy
Various factors discussed in the report below lead us to recommend a wait-and-watch approach to the company. The company recently regained rights to the drug from ex-partner Sanofi, and is set to conclude pivotal trials by next year. MyoKardia (MYOK) is a slowly developing story with a two-year window of opportunity for investors before the company faces regulators. The company targets symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a disease where the heart muscle becomes abnormally thick, ma...
Guru FocusMar 6
MyoKardia to Present at Cowen & Co. 39th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. ( MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of serious cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will present at the Cowen & Co. 39th Annual Health Care Conference on Wednesday, March 13th, 2019, at 10:40 a.m. ET in Boston, MA. A webcast of the presentation will be available by visiting the Investors section of MyoKardia’s ...
Stock Price, News, & Analysis for Myokardia
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which has completed Phase II clinical trial that is designed to reduce left ventricular contractility to potentially alleviate the functional consequences and symptoms of hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression. The company also develop...
Expected May 8